Please assess the completion status of the following clinical trial:

Trial Title: Feasibility Study of SOL (S-1,Oral Leucovorin,and Oxaliplatin) for Colorectal Cancer in China

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Advanced unresectable or recurrent colorectal cancer patients which meet the following criteria:~  * Willing to sign ICF~ * Could orally take investigational product~ * Pathology diagnosis is adenocarcinoma~ * Above 20 years~ * No previous treatment(including: radiotherapy,chemotherapy and immunotherapy)~ * For recurrent cases, if the patient had received adjuvant chemotherapy that didn't include S-1 and L-OHP in 180 days ago, he/she could be enrolled in~ * With target lesions with diameter which is longer than 1cm in spiral CT or MRI examination within 30 days~* Lab test within 15 days meet following criteria~  * Hemoglobin higher than 9.0g/dL~ * Leukocyte higher than 12,000/mm3~ * Neutrophil higher than 2,000/mm3~ * PLT higher than 10.0 104/mm3~ * Bilirubin lower than 1.5 times of upper limit of normal range~ * AST,ALT,ALP lower than 2.5 times of upper limit of normal range~ * Creatinine lower than upper limit of normal range~When patient has liver metastasis or bone metastasis, the value of AST,ALT,ALP could be within 5 times of upper limit of normal range~* ECOG 0 or 1~* Expected survival time more than 90 days~Exclusion Criteria:~* The patient who meet the following criteria should be excluded from this trial~* Patients who have severe drug allergic history(including: platinum related drugs,5-FU,FT,LV,5-HT3 receptor antagonist)~* Attended other clinical trial within 4 weeks~* Received transfusion of blood,related products or G-CSF within 15 days~* Received surgery within 4 weeks and the effect hadn't vanished~* Have diarrhea~* Have complication of active infection(infection caused fever higher than 38℃)~* Have complication of poor controlled hypercalcemia,hypertension,diabetes~* Have complication of severe ECG abnormal or other heart disease which will affect clinical treatment(including: cardiac dysfunction,myocardial infarction,angina)~* Have complication of severe pulmonary disease(including:interstitial pneumonia,pulmonary fibrosis,severe emphysema)~* Have complication of psychiatric disorder which will affect clinical treatment or have history of CNS disease~* Have complication of active gastrointestinal bleeding~* Have pleural effusion,ascites or pericardial effusion that need drainage~* Have complication of multiple bone metastasis~* Have severe complication(including:ileus,renal insufficiency,hepatic insufficiency,cerebrovascular disturbance)~* Have brain metastasis or suspicious brain metastasis~* Have active multiple primary cancer~* Female patients who are in pregnancy or lactation and patients who are not willing to take contraception measures~* Investigator judge not eligible to this trial

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- SOL (Type: EXPERIMENTAL): single arm

Based on this trial design, predict the completion outcome and termination type (if applicable).